Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Noxopharm Ltd. ( (AU:NOX) ) has shared an announcement.
Noxopharm Limited has released its Appendix 4G and Corporate Governance Statement for FY2025, highlighting its commitment to transparency and adherence to ASX governance standards. This announcement underscores the company’s dedication to maintaining robust corporate governance practices, which is crucial for its stakeholders and enhances its positioning within the biotech industry.
More about Noxopharm Ltd.
Noxopharm Limited is an innovative clinical-stage Australian biotech company focused on discovering and developing novel treatments for cancer and inflammation. The company is pioneering technology to improve the safety profile of a wide range of mRNA medicines and utilizes in-house capabilities and strategic partnerships to build a pipeline of proprietary drugs based on its Sofra™ and Chroma™ technology platforms.
Average Trading Volume: 265,437
Technical Sentiment Signal: Buy
Current Market Cap: A$30.68M
Learn more about NOX stock on TipRanks’ Stock Analysis page.